{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"793"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"}],"units":"Participants"}],"description":"Toxicities (adverse events) were evaluated using the modified Bearman Scale and the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.","groups":[{"description":"PREPARATIVE REGIMEN\\*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: \\*Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.\n\nfludarabine phosphate: 25 mg/m2 day -7 through day -3 prior to transplant\n\nmelphalan: 140 mg/m2 day -2 prior to transplant\n\nallogeneic hematopoietic stem cell transplantation: Cells infused on Day 0 of transplant regimen\n\nintensity-modulated radiation therapy: Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant","id":"OG000","title":"Treatment (Enzyme Inhibitor, Radiation Therapy, Transplant)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days post treatment","title":"Number of Grade 3 and Above Toxicities of Helical Tomotherapy (HT) in Combination With Fludarabine and Melphalan Followed by Allogeneic Stem Cell Transplantation.","type":"PRIMARY","unitOfMeasure":"events"}